Sana Biotechnology, Inc.

Informe acción NasdaqGS:SANA

Capitalización de mercado: US$1.1b

Sana Biotechnology Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Sana Biotechnology ha aumentado sus beneficios a una tasa media anual de 7.2%, mientras que la industria Biotechs ha visto sus beneficios crecer en un 34.1% anualmente.

Información clave

7.20%

Tasa de crecimiento de los beneficios

24.06%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs 17.04%
Tasa de crecimiento de los ingresosn/a
Rentabilidad financiera-137.04%
Margen neton/a
Última actualización de beneficios30 Jun 2026

Actualizaciones de resultados anteriores recientes

Recent updates

Seeking Alpha • Jul 22

Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation

Summary Sana Biotechnology is rated Sell due to excessive risk and overvaluation relative to its early-stage pipeline. Both lead assets, SC291 and SC451, are years from market and face low historical success rates, with SC291 only in Phase 1. The entire pipeline depends on the unproven Hypoimmune (HIP) platform; failure in early trials could invalidate the company. With $128.9M in cash and high burn, heavy dilution is likely for SANA, making the current $3.14 share price unjustified versus a $0.53 risk-adjusted fair value. Read the full article on Seeking Alpha
Seeking Alpha • Mar 25

Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421

Summary SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which also received FDA Fast Track for r/r SLE, extrarenal lupus, and lupus nephritis. However, UP421 might be the most promising. It restored insulin production in a type 1 diabetes patient. SANA also has ongoing Phase 1 trials for SC291 and SC262, with topline data expected in 2025. However, SANA does have high cash burn and dilution risks, which is why I just rate it a speculative “Buy”. Read the full article on Seeking Alpha
Seeking Alpha • Jan 08

Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success

Summary Sana Biotechnology, Inc. stock will be surging today after the company showed it can safely administer its allogeneic cell therapy for diabetes to a patient with no immunosuppression. Engineered cells were accepted by the patient's immune system without immunosuppression, a potential game-changing breakthrough that has stumped scientists for >75 years. Although the data is from a single patient, the potential market opportunity for a functional cure for Type 1 diabetes is immense. I rate SANA stock as a “Buy,” but advise caution as the stock may correct downward before long-term growth, given the early stage of clinical progress. Read the full article on Seeking Alpha
Seeking Alpha • Dec 04

Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus

Summary Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025. The FDA's Fast Track Designation for SC291 could expedite its review, addressing unmet medical needs in autoimmune disorders. Sana is also developing SC262 for relapsed/refractory B-cell malignancies, with data expected by the end of 2024 or in 2025. The global Lupus drugs market is expected to reach $4.2 billion by 2031. Read the full article on Seeking Alpha
Seeking Alpha • Nov 19

Sana Biotechnology: The Story Becomes Murkier

Summary Sana Biotechnology, Inc.'s stock has dropped from around $9 to under $2.50 since mid-March, when we last took a look at this engineered-cell therapy concern. Earlier this month, the company suspended two of its developmental programs to improve its pipeline focus and lower its cash burn rate to extend its “cash runway.”. The analyst community is also quite mixed around Sana Biotechnology's current prospects, but some additional trial data should be posted in the near future. An updated analysis around Sana Biotechnology follows in the paragraphs below. Read the full article on Seeking Alpha
Artículo de análisis • Nov 01

We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jul 14

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Summary Sana Biotechnology is a biotech company focused on developing engineered allogeneic cells for diseases with unmet clinical needs. Sana's most advanced product candidates leverage CRISPR technology to modify cells, with positive pre-clinical trial results and first in-human trials starting in late 2023. The company's pipeline includes oncology, autoimmune disease, and regenerative medicine product candidates, with a focus on UP421 and SC291 for T1DM and B-cell malignancies, respectively. Read the full article on Seeking Alpha
Artículo de análisis • Jul 12

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Mar 17

Sana Biotechnology: Now In Overbought Territory

Summary Sana Biotechnology's shares have risen some 60% since a secondary offering in February, driven by positive early clinical and research results. The company is focused on developing engineered cells to treat diseases, using a hypoimmune technology platform to create cells that evade immune detection. Sana has three clinical programs in Phase 1 trials, with promising results seen in the treatment of B-cell cancer and type I diabetes. A full analysis around Sana Biotechnology follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Jan 11

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Summary Sana Biotechnology's novel T1D treatment, not requiring immunosuppression, shows encouraging results in a non-human primate study. Sana displays improved Q3 financials with a current ratio of 4.03, but faces high cash burn and potential funding needs. Investment Stance: Shift from "Sell" to "Hold" based on Sana's financial management and R&D progress, with a watchful eye for further clinical and financial developments. Read the full article on Seeking Alpha
Artículo de análisis • Dec 30

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Artículo de análisis • Sep 14

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • May 26

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Dec 19

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Artículo de análisis • Sep 03

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Jun 27

Sana Biotechnology A Buy For Potential Cancer Therapies

Preclinical stage company has cash, expertise, and platform for success. Recent preclinical data showed potential of its technology. Clinical trials could begin in 2023, following INDs in 2022.
Artículo de análisis • May 16

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Desglose de ingresos y gastos

Cómo gana y gasta dinero Sana Biotechnology. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:SANA Ingresos, gastos y beneficios (USD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Jun 260-21245140
31 Mar 260-24244136
31 Dec 250-24444147
30 Sep 250-23449141
30 Jun 250-25253153
31 Mar 250-20959156
31 Dec 240-26764207
30 Sep 240-30668229
30 Jun 240-24573223
31 Mar 240-30973281
31 Dec 230-28373254
30 Sep 230-27667246
30 Jun 230-36263284
31 Mar 230-32061248
31 Dec 220-26967204
30 Sep 220-30056232
30 Jun 220-29854232
31 Mar 220-20753135
31 Dec 210-35650275
30 Sep 210-35847266
30 Jun 210-32741230
31 Mar 210-43334336
31 Dec 200-28528232
30 Sep 200-21525174
31 Dec 190-13122102

Ingresos de calidad: SANA actualmente no es rentable.

Margen de beneficios creciente: SANA actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: SANA no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 7.2% por año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de SANA en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: SANA no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (64.6%).

Rentabilidad financiera

Alta ROE: SANA tiene una rentabilidad financiera negativa (-137.04%), ya que actualmente no es rentable.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/08/18 02:22
Precio de las acciones al final del día2026/08/18 00:00
Beneficios2026/06/30
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Sana Biotechnology, Inc. está cubierta por 12 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Alec StranahanBofA Global Research
Samantha Lynn SemenkowCitigroup Inc
Reni BenjaminCitizens JMP Securities, LLC